Clinical trial
Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma
NCT00056134 · University Hospital Erlangen, Other · Completed
Key facts
| NCT number | NCT00056134 |
|---|---|
| Title | Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma |
| Official title | Vaccination of HLA-A1 and/or -A2+ Stage III or IV Melanoma Patients With Tumor Peptide-Loaded Autologous Dendritic Cells With Prior Depletion of CD25-Positive Cells Using Denileukin Difitox (ONTAK) |
| Lead sponsor | University Hospital Erlangen, Other |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Melanoma (Skin) |
| Intervention type | Biological |
| Interventions | Dendritic cell vaccine plus denileukin difitox |
| Enrollment | 23 |
| Start date | Oct 1, 2002 |
| Primary completion | Oct 1, 2011 |
| Completion | May 1, 2012 |
| First posted | Mar 7, 2003 |
| Last update posted | Feb 19, 2018 |
| Countries | Germany |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: